NCT03645499

An Open-Label Study to Assess Safety

An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

An Open-Label study to assess safety

Detailed description

An Open-Label study to assess the efficacy and potential for adrenal suppression following maximal use treatment with TA-102 topical formulations in subjects with Plaque Psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Topical TA-102 A	applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
DRUG	Topical TA-102 B	applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
DRUG	Topical TA-102 C	applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
DRUG	Topical TA-102 D	applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
DRUG	Topical TA-102 E	applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Timeline

• Start date: 2018-04-04
• Primary completion: 2019-10-24
• Completion: 2020-01-07
• First posted: 2018-08-24
• Last updated: 2022-12-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study